378 related articles for article (PubMed ID: 20706150)
1. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2010 Nov; 51(5):593-8. PubMed ID: 20706150
[TBL] [Abstract][Full Text] [Related]
2. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26422096
[TBL] [Abstract][Full Text] [Related]
3. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26121348
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease.
Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2008 May; 46(5):524-33. PubMed ID: 18493207
[TBL] [Abstract][Full Text] [Related]
6. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
[TBL] [Abstract][Full Text] [Related]
7. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease.
Gold BD; Gunasekaran T; Tolia V; Wetzler G; Conter H; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2007 Nov; 45(5):520-9. PubMed ID: 18030228
[TBL] [Abstract][Full Text] [Related]
8. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26422095
[TBL] [Abstract][Full Text] [Related]
9. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.
Labenz J; Armstrong D; Lauritsen K; Katelaris P; Schmidt S; Schütze K; Wallner G; Juergens H; Preiksaitis H; Keeling N; Nauclér E; Adler J; Eklund S
Aliment Pharmacol Ther; 2005 Nov; 22(9):803-11. PubMed ID: 16225489
[TBL] [Abstract][Full Text] [Related]
10. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
11. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis.
Katz PO; Ginsberg GG; Hoyle PE; Sostek MB; Monyak JT; Silberg DG
Aliment Pharmacol Ther; 2007 Mar; 25(5):617-28. PubMed ID: 17305763
[TBL] [Abstract][Full Text] [Related]
12. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
[TBL] [Abstract][Full Text] [Related]
13. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26121347
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
Goh KL; Benamouzig R; Sander P; Schwan T;
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):205-11. PubMed ID: 17301646
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable?
Boccia G; Manguso F; Miele E; Buonavolontà R; Staiano A
Am J Gastroenterol; 2007 Jun; 102(6):1291-7. PubMed ID: 17319927
[TBL] [Abstract][Full Text] [Related]
16. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Sharma P; Johnson DA; Monyak JT; Illueca M
Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Richter JE; Kahrilas PJ; Johanson J; Maton P; Breiter JR; Hwang C; Marino V; Hamelin B; Levine JG;
Am J Gastroenterol; 2001 Mar; 96(3):656-65. PubMed ID: 11280530
[TBL] [Abstract][Full Text] [Related]
18. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis.
Sjöstedt S; Befrits R; Sylvan A; Harthon C; Jörgensen L; Carling L; Modin S; Stubberöd A; Toth E; Lind T
Aliment Pharmacol Ther; 2005 Aug; 22(3):183-91. PubMed ID: 16091055
[TBL] [Abstract][Full Text] [Related]
19. Heartburn severity does not predict disease severity in patients with erosive esophagitis.
Fennerty MB; Johnson DA
MedGenMed; 2006 Apr; 8(2):6. PubMed ID: 16926745
[TBL] [Abstract][Full Text] [Related]
20. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy.
Kiesslich R; Kanzler S; Vieth M; Moehler M; Neidig J; Thanka Nadar BJ; Schilling D; Burg J; Nafe B; Neurath MF; Galle PR
Dig Dis; 2004; 22(2):221-7. PubMed ID: 15383765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
